Research programme: small molecule checkpoint inhibitors - Arbutus Biopharma
Alternative Names: PD-L1 inhibitor - Arbutus BiopharmaLatest Information Update: 16 Oct 2023
At a glance
- Originator Arbutus Biopharma
- Class Antineoplastics; Antivirals; Small molecules
- Mechanism of Action Checkpoint kinase inhibitors; Immunostimulants; Programmed cell death-1 ligand-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Liver cancer
- No development reported Hepatitis B